D-cycloserine: A Novel Treatment for Gulf War Illness (GWDCS)

Status unconfirmed · Phase 2 · Has a placebo group

Conditions studied: Gulf War Illness

In brief

The purpose of this study is to investigate the efficacy of d-cycloserine (DCS) treatment for Gulf War Illness (GWI). Gulf War veterans with Gulf War Illness experience numerous chronic health symptoms, including cognition and fatigue, which reduces their quality of life. Gulf War veterans are in urgent need of novel treatment plans to tackle elusive symptomatology of Gulf War Illness. By using the literature of previous studies, the investigators have chosen to investigate d-cycloserine as a possible candidate for treating GWI, specifically cognitive symptoms. DCS has been shown to reduce neuroinflammation, regulate glutamate levels, and improve synaptic functioning in key areas of the brain.

Key facts

Study ID
NCT02983734
Run by
Boston University Charles River Campus
People needed
56
Starts
2015-10-01
Expected to finish
2019-09-01
Last updated by the study team
2019-01-15

Who can join

Age: 43 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.